1001397-14-3Relevant academic research and scientific papers
Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available g protein-coupled receptor 119 agonists
Katamreddy, Subba R.,Carpenter, Andrew J.,Ammala, Carina E.,Boros, Eric E.,Brashear, Ron L.,Briscoe, Celia P.,Bullard, Sarah R.,Caldwell, Richard D.,Conlee, Christopher R.,Croom, Dallas K.,Hart, Shane M.,Heyer, Dennis O.,Johnson, Paul R.,Kashatus, Jennifer A.,Minick, Doug J.,Peckham, Gregory E.,Ross, Sean A.,Roller, Shane G.,Samano, Vicente A.,Sauls, Howard R.,Tadepalli, Sarva M.,Thompson, James B.,Xu, Yun,Way, James M.
, p. 10972 - 10994 (2013/02/25)
GPR119 is a 7-transmembrane receptor that is expressed in the enteroendocrine cells in the intestine and in the islets of Langerhans in the pancreas. Indolines and 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines were discovered as G protein-coupled receptor 119
Facile reductive amination of aldehydes with electron-deficient anilines by acyloxyborohydrides in TFA: Application to a diazaindoline scale-up
Boros, Eric E.,Thompson, James B.,Katamreddy, Subba R.,Carpenter, Andrew J.
scheme or table, p. 3587 - 3590 (2009/09/05)
A scale-up of diazaindoline 1 was achieved in four stages and 32% overall yield. The key step involved rapid reductive animation of aldehyde 8 with aniline 5 by sodium triacetoxyborohydride (STAB-H) and TFA followed by ring closure of intermediate amine 9
GPR119 AGONISTS FOR THE TREATMENT OF DIABETES AND RELATED DISORDERS
-
Page/Page column 64; 65, (2010/11/29)
The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.
